Abstract
The paucity of studies on the tricyclic antidepressants led us to conduct an investigation on 30 drug-free patients treated with amitryptyline in a double-blind protocol over a 4-week period. Consistent with previous reports, there was an immediate REM suppression on 50 mg, which was more pronounced at the 100-mg level. However, no significant incremental changes were noticed on 150 or 200 mg with regard to REM sleep suppression. Drug administration was associated with changes in other sleep variables such as stage 1 percent, stage 2 percent, and various measures of sleep continuity. The incomplete tolerance of the drug on certain REM sleep variables enhances our understanding of amitryptyline effects on the EEG sleep of depressed patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
